NCT04518306已完成3 期
Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Placebo for the Treatment of Hypertension
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 755
- 试验地点
- 43
- 主要终点
- Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
研究概览
简要总结
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to placebo.
详细描述
TRIAL DRUG:
GMRx2: single pill combination of telmisartan/amlodipine/indapamide Dose version 1: telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg Dose version 2: telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg INDICATION: Hypertension
TRIAL TITLE:
Efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •At screening visit:
- •Receiving 2 or more BP-lowering drugs.
- •Clinic seated mean SBP ≥160 mmHg and/or DBP ≥100 mmHg.
- •Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of contraception. Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
- •Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
- •Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to any of the 3 trial medications.
- •Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy.
- •Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
- •Current/history of New York Heart Association class III and IV congestive heart failure.
- •Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
- •Current/history of substantially uncontrolled diabetes (HbA1c > 11.0%) within last three months.
- •Current/history of end-stage renal disease or anuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m
- •Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal range within 6 months.
- •Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- •Arm circumference that is too large (>55 cm) or too small (<20 cm) to allow accurate measurement of BP.
- •Currently taking or might need during the trial, a concomitant treatment which is known to interact significantly with the trial medication: digoxin, lithium, diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors [e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, immunosuppressants.
- •Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP (see Error! Reference source not found.).
- •Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
- •Individuals working >2-night shifts per week.
- •Participated in any investigational drug or device trial within the previous 30 days.
- •History of alcohol or drug abuse within 12 months.
- •At randomization visit:
- •Unable to adhere to the trial procedures during the run-in period.
- •Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
- •High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high/low in clinic only; for example the clinical relevance of 'whitecoat hypertension' is uncertain.
- •High or low home DBP levels. The exact levels of DBP are not specified, reflecting clinical uncertainty of for example isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
- •Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- •Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
研究组 & 干预措施
Triple ¼ (GMRx2)
Experimental
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
干预措施: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg (Drug)
Triple ½ (GMRx2)
Active Comparator
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
干预措施: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4
时间窗: Randomization to Week 4
Each blood pressure (BP) measurement consisted of valid SBP values (ie. SBP\>60 mmHg and \<250 mmHg). BP values were summarized using descriptive statistics, including actual values and changes from randomization to Week 4, by timepoint and treatment groups.
次要结局
- Difference in Change in Clinic Seated Mean Mean Systolic Blood Pressure (SBP) From Randomization to Week 4(Randomization to Week 4)
- Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4(Randomization to Week 4)
- Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and DBP <90 mmHg at Week 4(At Week 4)
- Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4(At Week 4)
- Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4(Randomization to Week 4)
- Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 4(Randomization to Week 4)
- Difference in Change in Trough Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 4(Randomization to Week 4)
- Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 4(At Week 4)
- Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 4(Randomization to Week 4)
研究者
研究点 (43)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of HypertensionHypertensionNCT04518293George Medicines PTY Limited1,385
招募中
3 期
Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to placebo for the treatment of hypertension: An international, multi-center, randomized, double-blind, placebo-controlled, parallel-group trialHypertensionSLCTR/2023/009George Medicines Pty Limited
招募中
3 期
Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/indapamide) compared to dual combinations for the treatment of hypertension: An international, multi-center, randomized, double-blind, active-controlled, parallel-group trial.HypertensionSLCTR/2021/007Dr. Karl Roberts
进行中（未招募）
1 期
Efficacy and safety of GMRx2 compared to dual combinations for the treatment of high blood pressureMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2020-004196-40-PLGeorge Medicines Pty Ltd1,500
进行中（未招募）
1 期
Efficacy and safety of GMRx2 compared to dual combinations for the treatment of high blood pressureHypertensionEUCTR2020-004196-40-CZGeorge Medicines Pty Ltd1,500